Qilian International Holding Group Limited - Asset Resilience Ratio

Latest as of March 2025: 2.36%

Qilian International Holding Group Limited (BGM) has an Asset Resilience Ratio of 2.36% as of March 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Qilian International Holding Group Limit (BGM) total liabilities for a breakdown of total debt and financial obligations.

Liquid Assets

$4.89 Million
Cash + Short-term Investments

Total Assets

$207.39 Million
All company assets

Resilience Assessment

Low
Financial Resilience Level

Asset Resilience Ratio Trend (2018–2024)

This chart shows how Qilian International Holding Group Limited's Asset Resilience Ratio has changed over time. See Qilian International Holding Group Limit shareholders equity for net asset value and shareholders' equity analysis.

Liquid Assets Composition Over Time

This chart breaks down Qilian International Holding Group Limited's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Qilian International Holding Group Limit (BGM) total market value.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents $0.00 0%
Short-term Investments $4.89 Million 2.36%
Total Liquid Assets $4.89 Million 2.36%

Asset Resilience Insights

  • Limited Liquidity: Qilian International Holding Group Limited maintains only 2.36% of assets in liquid form.
  • This low level may indicate efficient asset utilization but could pose risks during economic downturns.
  • The company has significant short-term investments, indicating active treasury management.

Qilian International Holding Group Limited Industry Peers by Asset Resilience Ratio

Compare Qilian International Holding Group Limited's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Changchun High & New Technology Industries Group Inc
SHE:000661
Drug Manufacturers - Specialty & Generic 3.73%
Yuhan Corp.
KO:000100
Drug Manufacturers - Specialty & Generic 0.99%
Tasly Pharmaceutical Group Co Ltd
SHG:600535
Drug Manufacturers - Specialty & Generic 9.09%
Zhejiang Hisun Pharmaceutical Co Ltd
SHG:600267
Drug Manufacturers - Specialty & Generic 0.02%
Zhejiang Jiuzhou Pharm Co Ltd
SHG:603456
Drug Manufacturers - Specialty & Generic 0.01%
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091
Drug Manufacturers - Specialty & Generic 26.36%
Jiangsu Kanion Pharmaceutical Co Ltd
SHG:600557
Drug Manufacturers - Specialty & Generic 0.29%
Cronos Group Inc
TO:CRON
Drug Manufacturers - Specialty & Generic 69.94%

Annual Asset Resilience Ratio for Qilian International Holding Group Limited (2018–2024)

The table below shows the annual Asset Resilience Ratio data for Qilian International Holding Group Limited.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2024-09-30 15.70% $8.32 Million $53.00 Million -13.45pp
2023-09-30 29.15% $14.94 Million $51.26 Million --
2022-09-30 0.00% $0.00 $64.53 Million --
2019-09-30 0.00% $0.00 $35.27 Million --
2018-09-30 0.04% $14.58K $33.34 Million --
pp = percentage points

About Qilian International Holding Group Limited

NASDAQ:BGM USA Drug Manufacturers - Specialty & Generic
Market Cap
$54.37 Million
Market Cap Rank
#21571 Global
#4588 in USA
Share Price
$0.30
Change (1 day)
+2.73%
52-Week Range
$0.29 - $16.36
All Time High
$58.32
About

BGM Group Ltd., through its subsidiaries, operates as a pharmaceutical and chemical company in China. It offers oxytetracycline products, including Qilian Shan oxytetracycline tablets to prevent and treat a range of diseases in chickens, turkeys, cattle, swine, and human; and Qilian Shan oxytetracycline active pharmaceutical ingredients, which are used by pharmaceutical companies in the manufactu… Read more